Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
01/13/2026 07:00 AM • Kymera Therapeutics announced its 2026 clinical and preclinical milestones, including ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected in 2027, initiation of Phase 1 testing for KT-579 in Q1 2026, and advancement of at least one new development candidate toward IND. The company maintains $1.6 billion in cash with runway into 2029.
KYMR - Company announced strong 2026 objectives with multiple clinical milestones, positive Phase 1b data for KT-621 showing efficacy comparable to dupilumab, FDA Fast Track designation, robust cash position of $1.6 billion with runway into 2029, and expansion of pipeline with new development candidates. Successful execution of strategy and clinical progress support positive outlook.
Investing.com • Brett Owens